The European Commission has green-lighted Qtern (saxagliptin/dapagliflozin) for the treatment of type II diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway.
News
UK charity triples investment in pancreatic cancer research
Cancer Research UK says it has tripled its investment in pancreatic cancer research, as the number of cases and deaths from the disease continues its upward trend.
EU clears Gilead’s pan-genotypic hepatitis C therapy
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by European regulators to treat all six types of the virus, potentially eliminating the need for genotype testing.
US regulators expand use of Boehringer/Lilly’s diabetes drug
US regulators have expanded the scope of Boehringer Ingelheim and Eli Lilly’s Synjardy to include treatment-naïve adults with type II diabetes.
FDA advisors back brodalumab with suicide risk plan
Valeant’s skin jab brodalumab has taken a big step towards US approval after regulatory advisors backed the drug for adult patients with moderate-to-severe plaque psoriasis.
Celgene, Jounce in $2.6-bn immuno-oncology deal
Celgene and Jounce Therapeutics have linked in a global strategic collaboration striving to develop and commercialise immuno-oncology treatments.
Inquiry finds NHS funding promises ‘misleading’
The funding set aside for the National Health Service in the spending review is in reality less than would appear to be the case from official pronouncements, a report by the Commons Health Committee has concluded.
EU to review Samsung Bioepis’ Humira biosimilar
European regulators have agreed to review Samsung Bioepis’ SB5, a biosimilar version of AbbVie’s Humira, the world’s second-best selling drug.
Sanofi Pasteur MSD’s shingles jab OK’d for UK’s immunisation scheme
Sanofi Pasteur MSD’s shingles (herpes zoster) vaccine has been cleared for continued use in the UK’s national immunisation programme for at least the next two years, following an evaluation of the vaccine’s clinical and cost effectiveness.
BMS’ Opdivo gets US, EU reviews for head and neck cancer
Regulators on both sides of the Atlantic have agreed to review Bristol-Myers Squibb’s immunotherapy Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
ViiV’s HIV therapy Triumeq shows efficacy in women
ViiV Healthcare’s Triumeq has come out on top in a late-stage study pitting its effectiveness in treating women with HIV against that of an atazanavir-based regimen.
Roche’s Gazyva fails to hit target in lymphoma trial
Roche’s new blood cancer drug Gazyva has failed to show significant improvements versus veteran therapy MabThera/Rituxan in patients with previously untreated diffuse large B-cell lymphoma, marking a setback in plans to protect sales from biosimilar competition.
Cancer the most common killer, ONS data shows
Cancer was the most common broad cause of death in England and Wales last year, according to the latest data from the Office of National Statistics.
Celgene’s Revlimid approved for Mantle Cell Lymphoma
Celgene’s Revlimid has been approved by European regulators to treat patients with relapsed/refractory Mantle Cell Lymphoma (MCL), a rare sub-type of aggressive non-Hodgkin’s lymphoma (NHL).
EU regulators to take another look at Merck’s MS pill
European regulators have accepted for review Merck’s application to market investigational drug cladribine for the treatment of relapsing-remitting multiple sclerosis.
